Novartis
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Novartis sits in the top decile of US sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count).
Novartis: 265 sponsored US clinical trials, none currently recruiting.
Novartis sponsors 265 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 248 completed. 176 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 11 trials.
Top-decile sponsor footprint
Novartis ranks in the top decile of sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 264 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
265 total, page 6 of 6
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
NCT00367978
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00029224
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00014638
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
NCT00006475
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
NCT00006053
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00006343
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
NCT00006052
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
NCT00130845
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
NCT00006269
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
NCT00131144
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
NCT00003884
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
NCT00002394
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
NCT00000174
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
NCT00124241
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
NCT00243763
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 46 |
| Phase 3 | 126 |
| Phase 4 | 50 |
Therapeutic Areas
How the Novartis archive is shaped
265 indexed studies, none listed as recruiting (0% open); 248 completed (94%).
Phase mix: 176 late (III/IV) vs 69 early (I/II) (later-stage heavy).
Top condition: Hypertension (11 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novartis: archived-pipeline peers nationwide
Peers matched on 265 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novartis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 265 archived trials
- Abbott Medical Devices · 261 trials · 9% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Pennington Biomedical Research Center · 258 trials · 13% recruiting
- University of Texas at Austin · 257 trials · 23% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novartis page
265 registered trials is a research-attention snapshot, not an endorsement of Novartis or any single study.
- None of Novartis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertension is the condition Novartis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis pipeline card: 265 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.